Barrett Asset Management LLC Has $745,000 Position in Zoetis Inc. (NYSE:ZTS)
Barrett Asset Management LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 59.2% during the second quarter, Holdings Channel reports. The institutional investor owned 11,940 shares of the company’s stock after buying an additional 4,440 shares during the period. Barrett Asset Management LLC’s holdings in Zoetis were worth $745,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Guardian Life Insurance Co. of America boosted its stake in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the last quarter. Sii Investments Inc. WI boosted its stake in shares of Zoetis by 0.3% in the first quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock valued at $383,000 after buying an additional 23 shares during the last quarter. Argent Trust Co boosted its stake in shares of Zoetis by 0.8% in the first quarter. Argent Trust Co now owns 4,132 shares of the company’s stock valued at $221,000 after buying an additional 32 shares during the last quarter. Ironwood Investment Management LLC boosted its stake in shares of Zoetis by 0.7% in the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock valued at $429,000 after buying an additional 48 shares during the last quarter. Finally, CENTRAL TRUST Co boosted its stake in shares of Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock valued at $142,000 after buying an additional 49 shares during the last quarter. 94.51% of the stock is owned by hedge funds and other institutional investors.
Zoetis Inc. (ZTS) opened at 61.83 on Tuesday. The firm’s 50-day moving average price is $62.59 and its 200-day moving average price is $57.66. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $63.85. The company has a market capitalization of $30.35 billion, a price-to-earnings ratio of 35.95 and a beta of 1.02.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Thursday, June 15th will be given a $0.105 dividend. This represents a $0.42 annualized dividend and a yield of 0.68%. The ex-dividend date is Tuesday, June 13th. Zoetis’s dividend payout ratio (DPR) is presently 24.42%.
Several analysts have issued reports on the company. Hilliard Lyons assumed coverage on Zoetis in a research note on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective on the stock. Credit Suisse Group upped their price objective on Zoetis from $61.00 to $67.00 and gave the company an “outperform” rating in a research note on Wednesday, May 24th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price objective on the stock in a research note on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a research note on Monday. Finally, Cowen and Company set a $70.00 price objective on Zoetis and gave the company a “buy” rating in a research note on Monday, July 17th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $64.78.
In related news, insider Catherine A. Knupp sold 5,785 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.16, for a total value of $348,025.60. Following the completion of the transaction, the insider now owns 24,415 shares in the company, valued at approximately $1,468,806.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.31% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.